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Abstract
Spatiotemporal characterization of protein–protein interactions (PPIs) is essential in determining
the molecular mechanisms of intracellular signaling processes. In this review, we discuss how new
methodological strategies derived from non-invasive fluorescence- and luminescence-based
approaches (FRET, BRET, BiFC and BiLC), when applied to the study of G protein-coupled
receptor (GPCR) oligomerization, can be used to detect specific PPIs in live cells. These
technologies alone or in concert with complementary methods (SRET, BRET or BiFC, and SNAP-
tag or TR-FRET) can be extremely powerful approaches for PPI visualization, even between more
than two proteins. Here we provide a comprehensive update on all the biotechnological aspects,
including the strengths and weaknesses, of new fluorescence- and luminescence-based
methodologies, with a specific focus on their application for studying PPIs.
Background
Biological processes proceed through a sequence of specific protein–protein interactions
(PPIs) along intracellular signaling cascades. Characterization of these interactions is thus
essential to the understanding of cellular mechanisms. Using genetic approaches (e.g. yeast
two-hybrid screens) [1,2], it is possible to reveal new PPIs, which are subsequently
confirmed and validated by additional biochemical approaches, such as immobilized PPI
assays (e.g. co-immunoprecipitation and pull-down assays) [3]. The combination of genetic
and biochemical approaches is therefore a powerful tool for the identification of novel PPIs.
However, this combined approach suffers from two major drawbacks: first, it does not
provide spatiotemporal information on a specific PPIs occurring within live cells; and
second, it requires mechanical-, chaotropic- or detergent-based cell lysis, which can alter
native PPIs [4]. To overcome these drawbacks, new imaging technologies have been
described recently that are based on the detection of resonance energy transfer (RET)
between fluorescent or luminescent proteins (FPs or LPs) (Box 1) [5] and on protein
fragment complementation approaches [6,7], both of which facilitate real-time
characterization and visualization of PPIs in live cells.
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In the late 1940s, Theodor Förster described the basic principle of RET [81], which
consists of nonradiative (dipole–dipole) transfer of energy from an excited chromophore,
known as the donor, to an acceptor molecule [82]. This transfer of energy – called Förster
resonance energy transfer (FRET) – results in a decrease in donor emission paralleled by
an increase in acceptor emission. The efficiency of this energy transfer (ERET) is
inversely proportional to the sixth power of the distance (R) between donor and acceptor
molecules according to the following equation,
where R0 is the distance for 50% energy transfer from the donor to the acceptor, which is
typically approximately 5 nm (the effective range for energy transfer is <10 nm). RET
depends not only on the distance between the donor and acceptor molecules, but also on
the orientation of their polarization [83]. The sensitivity of RET measurements is within
the boundary for conventional protein dimensions [84] and for the distances described for
multimeric protein complexes observed in biological systems [85].
RET efficiency also depends on other variables: (i) the orientation angle between donor
and acceptor molecules; (ii) the degree of spectral overlap between donor emission and
acceptor excitation; (iii) the quantum yield of the donor; and (iv) the extinction
coefficient of the acceptor [81,83]. Thus, when choosing two chromophores for a RET
process, it is necessary to select those with the highest donor-quantum yield and
absorbing acceptor that have significant spectral overlap [86]. For inter- or intramolecular
FRET between CFP and YFP, for example, FRET can be monitored as the YFP/CFP
emission intensity ratio on excitation at 436 nm according to the following equation:
where FYFPex436/em535 and FCFPex436/em480 represent the emission intensity for YFP at
535 nm and CFP at 480 nm on excitation at 436 nm; a and b are correction factors for
CFP bleedthrough into the 535-nm channel and crosstalk due to the direct YFP excitation
by light at 436 nm, respectively. FYFPex500/em535 is the YFP emission intensity at 535 nm
on excitation at 500 nm, which is recorded at the beginning of each experiment.
Progress in various fluorescence- and luminescence-based approaches has paralleled the
study of G protein-coupled receptor (GPCR) oligomerization. GPCRs are the largest family
of cell surface receptors and are the targets of a large array of extracellular chemical (e.g.
neurotrans-mitters, hormones) and sensory (light, taste and odorant molecules) stimuli, as
well as many clinical drugs (e.g. β-blockers and antipsychotics). Several biochemical and
crystal structure studies [8,9] have confirmed that GPCRs comprise seven α-helical
transmembrane structures connected by intra- and extracellular loops, with N-terminal
extracellular and C-terminal intracellular domains. Receptor activation through binding of a
ligand agonist proceeds by conformational rearrangement within the transmembrane helical
domain as the receptor switches from an inactive to an active state, which in turn activates
heterotrimeric G proteins (Gαβγ) [10,11]. Activated G proteins regulate the levels of
intracellular second-messenger molecules (Ca2+, cAMP, phoshoinositides, cGMP), which
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modulate signaling cascades involving kinases such as PKA, PKC, PKG and CMKII, among
others [12].
Traditionally, it has been considered that GPCRs signal exclusively as single monomeric
entities [13]. However, emerging studies have revealed the existence of receptor homo- and
heterodimers in many cell types (neuronal, cardiac, endocrine) [14,15]. For example,
adenosine A2A and dopamine D2 receptor heterodimers at the cell surface of striatopallidal
GABAergic neurons have opposite effects. Adenosine inhibits dopamine-induced locomotor
activity in the basal ganglia [16], thereby exerting finely tuned control of neural activity in
response to adenosine and dopamine. The detection of specific receptor–receptor
interactions is therefore a first step in understanding how GPCR oligomers modulate cell
signaling in response to multiple ligands. Hence, here we review recent developments in FP-
and LP-based technologies in the context of GPCR oligomerization, specifically focusing on
cases where the receptor oligomers accomplish established recognition and acceptance NC-
IUPHAR (the International Union of Basic and Clinical Pharmacology Committee on
Receptor Nomenclature and Drug Classification) criteria, including evidence for physical
association in native tissue or primary cells, demonstration of a specific functional property
for the oligomer, and in vivo evidence of its existence [17]. The ensuing discussion of GPCR
oligomer function in living cells is extended to the study of mutiprotein complexes in their
physiological environments.
Applying intermolecular RET to the study of PPIs
Fluorescence RET (FRET)
Classical RET techniques, including fluorescence RET (FRET) and bioluminescence RET
(BRET), use the non-radiative transfer of energy (Box 1) between donor and acceptor
fluorescent molecules as a measure of their proximity. For example, cyan (CFP) and yellow
(YFP) variants of the green fluorescent protein (GFP) can be used for FRET in live cells.
When CFP is excited and FRET occurs, CFP emission decreases and YFP emission
increases (Figure 1a). The presence of specific receptor homo- or heterocomplexes in
transfected cells can therefore be detected by FRET measurements between two receptors,
usually tagged at the C-terminus with either CFP (R1CFP) or YFP (R2YFP), because dimer
formation between R1CFP and R2YFP causes a RET process between fluorophores (Figure
1a).
For specific receptor–receptor interactions, the efficiency of energy transfer between CFP
and YFP can be measured by donor fluorescence recovery after acceptor photobleaching
(DFRAP). The efficiency increases as a hyperbolic function of the concentration of R2YFP,
as determined by the YFP emission intensity (Figure 1b). However, nonspecific FRET due
to random distribution and collisions between CFP and YFP molecules in the plasma
membrane can be assessed by the expression of pairs of N-terminal membrane-tagged CFP
and YFP molecules [18]. In this case, the FRET efficiency increases as a function of the
acceptor molecule concentration; consequently, high non-physiological concentrations of the
acceptor are needed to achieve saturation. Thus, prompt saturating behavior is expected for
proteins forming specific oligomers, which prevents nonspecific FRET resulting from
random collisions of overexpressed fluorescent proteins [19]. Interestingly, the latter issue
constitutes a common problem in most RET-based methods. With respect to FRET, several
techniques can overcome this drawback; for instance, fluorescence lifetime imaging (FLIM)
is largely independent of fluorophore concentrations [20,21], and DFRAP is less sensitive to
unbalanced expression levels of fluorescent proteins [22].
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The major limitations encountered with experiments using CFP–YFP as a FRET pair –
specifically, crosstalk (direct acceptor excitation by light used to excite the donor; Box 1),
bleedthrough (partial overlap of donor and acceptor emission wavelengths) and
photobleaching [5] (Table 1) – can be circumvented by time-resolved FRET (TR-FRET) or
BRET approaches. TR-FRET uses Eu3+ cryptate as a donor molecule and either Alexa Fluor
647 or allophycocyanin (APC) as an acceptor molecule. The advantage of this approach is
the long-lived (300–1000 μs) emission fluorescence of Eu3+ cryptate, which facilitates
prolonged excitation of the acceptor molecule in the absence of an external continuous
excitation source [23,24]. In addition, the very weak emission of Eu3+ at the acceptor
emission wavelength (e.g. 665 nm for APC) considerably reduces bleedthrough [23].
Consequently, this approach can largely increase the signal-to-noise ratio owing to both the
long lifetime of Eu3+ and negligible bleedthrough emission at the acceptor emission
wavelength.
TR-FRET has been used extensively to validate the existence of GPCR oligomers at the
surface of living cells using fluorescently labeled antibodies specific for target receptors.
This method has provided evidence of constitutive oligomerization of the δ-opioid receptor,
with expression of combinations of N-terminal c-Myc- and Flag™-tagged forms of the δ-
opioid receptor in HEK293 cells, such as R1Myc and R2Flag, respectively (Figure 1c); a
Eu3+-labeled (K) anti-c-Myc antibody was used as an energy donor with an APC-labeled
anti-Flag™ antibody as an acceptor [25]. It is noteworthy that the major potential limitation
for the TR-FRET approach is related to the use of antibodies. Antibody size (150 kDa) can
either increase the FRET signal due to random collisions or hamper oligomer assembly. In
addition, it is difficult to ascertain if oligomerization of the partners is not promoted by the
bivalent nature of the antibodies [26].
Bioluminescence RET
Bioluminescence RET (BRET) depends on the bioluminescent enzyme luciferase from
Renilla reniformis (Rluc), rather than CFP, to produce emitted light compatible with YFP
excitation [27]. The interactions between receptors R1 and R2 tagged with Rluc and YFP
(R1RLuc and R2YFP, respectively) can thus be detected by BRET in a similar manner as
described for FRET (Figure 1a). Saturation BRET experiments have been extensively used
to characterize specific interactions between GPCRs [26]. Typically, these experiments
consist of expression of a constant amount of the donor-labeled protein (R1Rluc) with
increasing amounts of the acceptor-labeled protein (e.g. R2YFP), followed by incubation
with the luciferase substrate and detection of the resulting BRET signal [27]. The acceptor
concentration that generates a half-maximal BRET signal (BRET50) is often used as a
parameter to express the relative binding affinity between two receptors. However, BRET50
is difficult to interpret if the association between receptors is irreversible.
Although promising single-cell BRET imaging has been recently performed [28,29],
subcellular BRET is difficult to detect because the luciferase substrate cannot be dispensed
to a specific cellular domain. This issue is highly important when RET-tagged proteins are
overexpressed, such as in transient transfection experiments; accumulation of these proteins
in intracellular organelles (e.g. endoplasmic reticulum, Golgi apparatus and trafficking
vesicles) can lead to nonspecific energy transfer by random collisions, thus hindering
positive identification of RET events resulting from direct interaction between proteins at
the cell surface [30–32].
Ciruela et al. Page 4













PPIs at the surface of a living cell
The difficulties encountered with classical RET techniques for analysis of GPCR homo- and
heterocomplex assembly at the cell surface can be circumvented using the SNAP-tag
technology (Table 1) [33]. The SNAP-tag method is based on irreversible and specific
reaction of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT) with O6-
benzylguanine (BG) derivatives, which can be selectively labeled with a variety of chemical
fluorophores (Figure 1c). The first remarkable characteristic of this tool is its high
versatility; multiple types of experiments can be performed, such as fluorescence
microscopy applications, protein purification, and PPI analysis, because AGT can be fitted
with various labels. Second – and even more advantageous in the field of GPCR
oligomerization – this tool can overcome some limitations of the classical fusion of auto-
fluorescent proteins to the protein of interest. Thus, the small size of AGT (24 kDa) affects
protein function in living cells to a lesser extent than GFP, especially when oligomerization
occurs. Furthermore, fluorescent labeling is achieved after protein expression in the
membrane and it has been demonstrated that fluorescently labeled AGT-fusion proteins are
very stable, thus facilitating analysis of the dynamics of cell-surface protein complexes in
living cells [33–35].
The SNAP-tag methodology has recently been used to study GPCR oligomerization [36]. In
this study, distinct GPCRs (e.g. GABAB receptors) were tagged at the N-terminus with AGT
(R1AGT). BG derivatives were then prepared, carrying Eu3+ cryptate as a donor and d2 (an
organic moiety that emits at approx. 665 nm) as an acceptor on the benzyl group.
Alternatively, TR-FRET was measured between Flag-GABAB receptors (R2Flag) labeled
with d2 antibodies and SNAP-tag fusion proteins labeled with BG-Eu3+-cryptate (BGK)
(Figure 1c). This SNAP-tag and TR-FRET combined approach facilitated rapid, easy and
quantitative assessment of cell surface interactions and confirmed the oligomeric assembly
of distinct GPCRs at the cell surface [36].
Another technique for specific labeling of multiple proteins in a single cell has recently been
described [37]. This study used the CLIP-tag tool (based on the SNAP-tag technology) for
which an AGT mutant was generated to selectively accept a substrate other than BG. The
new substrate was O6-benzylcytosine (BC), which has sufficient specificity for orthogonal
labeling; thus, BC only reacted with the mutant AGT version (CLIP-tag) and not with the
wild-type AGT (SNAP-tag), which could be labeled specifically with BG. Therefore, the
presence of specific receptor homo- or heterocomplexes in transfected cells could be
detected by FRET measurements between two receptors fused at the N-terminus with the
two AGT variants (i.e. SNAP-tag and CLIP-tag). Once expressed at the plasma membrane,
these receptor constructs were specifically labeled with BG and BC derivatives carrying
distinct FRET-compatible fluorophores (BGCy3 and BCCy5, respectively) (Figure 1c).
Recently, a non-RET-based technique based on fluorescence recovery after photobleaching
(FRAP) was used to investigate GPCR oligomerization at the plasma membrane [38]. In
brief, after immobilization of a defined fraction of receptors with antibodies, the lateral
mobility of the non-immobilized fraction was measured by FRAP [38]. Thus, this FRAP
approach can be used to determine the stability of oligomers at the plasma membrane and to
quantify and distinguish between heteromerization and higher-order oligomerization of
human β-adrenoceptors [38].
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Protein-fragment complementation assays toward the study of protein
oligomerization
Protein-fragment complementation assays (PCAs) facilitate direct detection of PPIs and the
study of their dynamic events in living cells [39,40]. In brief, PCAs consist of the structural
and functional reconstitution of an active protein, typically an enzyme or FP, from two
inactive halves that are genetically fused to the interacting proteins of interest. When FP or
LP fragments are used for complementation, these assays are known as bimolecular
fluorescence or luminescence complementation (BiFC/BiLC). Both BiFC and BiLC rely on
the generation of a fluorescent or luminescent signal from two non-fluorescent or non-
luminescent fragments of an FP or LP when brought in close proximity by fusion partners
[4]. It is important to note that BiLC, in contrast to BiFC, generates complemented LPs (e.g.
Rluc) that assemble mostly in a reversible fashion, thus facilitating real-time measurements
of protein–protein association and dissociation and providing dynamic information on the
interaction [41,42]. It is important to consider that not all complemented LPs are reversible
and that the affinity and kinetics of the BiLC process might interfere with and change the
PPI under study. BiLC assays, in contrast to BiFC, are not suitable enough to provide
information about the subcellular localization of the interaction. Indeed, luciferases have a
low quantum yield, so a specialized detection system is required to record luminescence
images, such as a microscope coupled to an intensified charge-coupled device (CCD)
camera, in addition to long exposure times.
To date, the BiFC approach has been successfully used to visualize more than 200 PPIs in
different models [40,43–45]. BiLC has also been used successfully in the detection of
protein interactions in living animals, taking advantage of its high signal-to-noise ratio
[46,47]. Interestingly, fluorescence- and luminescence-based approaches can also be used in
the study of the GPCR downstream machinery (i.e. G proteins or scaffolding proteins)
[48,49]. Toward this end, the BiFC assay was used to visualize specific dimers between the
β and γ subunits of G proteins. Briefly, an N-terminus fragment of YFP was fused to Gβ
(R1N-YFP) and a C-terminus fragment of YFP to Gγ (R2C-YRP); when expressed together in
HEK-293 cells, a fluorescent signal was obtained (Figure 2a). These experiments
demonstrated the functionality of the Gβγ complex in the plasma membrane and revealed
the role of the different subunits in subcellular targeting [50].
The BiFC method, which facilitates direct subcellular visualization of protein interactions in
living cells, has several advantages compared to the RET techniques described above (Table
1). Essentially, BiFC is a more sensitive technique because the complementation process
produces a new fluorescent signal, whereas RET methods produce changes in existing
fluorescence, and thus have some detection drawbacks (Box 1). Although BiFC assays are
powerful tools in the study of PPIs, they have limitations that might preclude their extensive
use: the inherent irreversible association of the fluorescent-protein fragments [44]; the
intrinsic ability of the FP halves to spontaneously associate under certain circumstances
[45,51]; and the time required for fluorophore maturation (Table 1). RET approaches can be
used for reversible analysis of protein complex formation (protein–protein association and
dissociation), so they should be ideal choices for PPI kinetic studies. RET approaches and
BiFC methods are complementary and consequently an experimental tradeoff exists between
the dynamism of RET and the sensitivity of BiFC when analyzing PPIs (Table 1).
Interestingly, some investigators have tried to combine both approaches. As an example,
BRET and BiFC combined results led to the proposal of a new protein composition for the
calcitonin gene-related peptide receptor. The authors concluded that dual BRET/BiFC is a
powerful tool for analysis of constitutive and dynamically regulated multiprotein complexes
[52].
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Multicolor BiFC has also been developed to simultaneously visualize several interactions
within one cell [53]. This assay is based on the generation of complemented FPs by the
association of fragments originating from different FPs. These new complemented FPs
possess distinct spectral properties when compared to the native FPs [53,54]. For instance,
Venus and Cerulean FPs (which are GFP derivatives of yellow and cyan FPs, respectively)
can be used in this approach. The complementation between Venus N-terminal (VN) and
Cerulean C-terminal (CC) fragments results in a green-shift in emission compared with
reconstitution of the original Venus or Cerulean FPs [53,54].
The multicolor BiFC approach has also been used to simultaneously visualize the relative
formation of distinct GPCR oligomeric species and monitor the effect of receptor ligands on
the oligomeric status via ratiometric fluorescence [55,56]. For instance, the drug-induced
changes in adenosine A2A receptor and dopamine D2 receptor homo- and heterodimers were
assessed in living cells [56]. In brief, the D2R fused to the R1VN was co-transfected in a
variant of the Cath.a CAD cell line with A2AR fused to the N- (R2CN) or C-terminal (R2CC)
fragment of the Cerulean FP. Venus (A2AR–D2R heterodimer, R1VN–R2CC) and Cerulean
(A2AR–A2AR homodimers, R2CN–R2CC) fluorescent signals coexisted and were largely co-
localized at the plasma membrane and in intracellular vesicular structures, facilitating
simultaneous visualization of the distinct receptor oligomers within a cell (Figure 2b).
Interestingly, when these cells were treated with the D2R agonist quinpirole, Venus
fluorescence was decreased compared with Cerulean fluorescence in the plasma membrane,
indicating a ratiometric decrease in the A2AR–D2R heterodimer with respect to the A2AR–
A2AR homodimer (Figure 2c). Overall, these results demonstrate one of the first BiFC
applications in monitoring drug-mediated GPCR oligomerization modulation. Multicolor
BiFC could theoretically shed light on the earlier proposed paradigm that GPCR
oligomerization is altered in pathological conditions such as Parkinson’s disease [57–59].
Consequently, this approach could potentially facilitate screening of drugs that impinge on
the stoichiometry of a named GPCR oligomer (e.g. A2AR–D2R heterodimer), which would
have high clinical impact [59].
Detection of higher-order protein complexes
The RET techniques described above are well-suited for detection of interactions between
two proteins that form homo- or heterodimer complexes; however, a given protein can also
be part of multiprotein complexes involving numerous interactions with different receptor
partners. The formation of highly organized protein structures can be extremely specific,
especially if they dictate the final functional output of a specific receptor oligomer. Thus, the
existence of high-order oligomer complexes has been detected for some GPCRs [60–62],
including rhodopsin (by means of atomic force microscopy [63–65]) and the α1b-
adrenoceptor, for which high-order oligomer formation is required for receptor maturation,
surface delivery and function [61]. Notably, such highly organized protein structures have
not been found for some other GPCRs. In fact, rhodopsin oligomerization remains
controversial and it has been suggested that the native protein might not form a high-order
complex [66]. It has also been demonstrated that metabotropic glutamate receptors (mGluR)
homodimers are not in contact with each other at the surface of HEK-293 cells and a higher-
order oligomer is not formed [67].
It has been postulated that to modulate GPCR function, GPCR homo- and heterodimers can
be interconnected at the plasma membrane, forming higher-order oligomers, which are also
termed receptor mosaics (RMs) [57,68,69]. In a named RM, the interconnected receptors
would display cooperativity phenomena; thus, these high-order oligomers behave as
computational processors that directly integrate and transmit assorted simultaneous signals
into the cell [70]. Consequently, RMs constitute potential drug targets in the treatment of
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some diseases. A high-order oligomer, A2AR-D2R-mGlu5R, has been described [71] in
which D2R actions are allosterically modulated by the other two receptors within the
oligomer hub, which could explain, for instance, the observed positive action of A2AR
antagonists combined with D2R agonists in the management of Parkinson’s disease [59].
Sequential RET (SRET)
Fluorescence-based techniques have played valuable roles in characterizing higher-order
receptor complexes. One of the first approaches described for analysis of interactions
between several proteins by means of fluorescence microscopy was called three-
chromophore fluorescence resonance energy transfer (3-FRET) [72]. This method was used
to detect trivalent α1b adrenoceptor complexes in living cells [60–62]. Later, SRET was
developed in which the acceptor from a first RET pair serves as the donor for a second RET
process. Therefore, in the SRET experimental approach shown in Figure 3a, the
bioluminescence emission produced by catabolism of the Rluc substrate (R1Rluc) provides
the first energy for transfer (BRET) to a proximal FP acceptor (R2GFP2), assuming the RET
principle is achieved (Box 1). The initial FP acceptor can then engage in a second RET
process, thus becoming a donor FP in the transfer of energy (FRET) to a downstream
acceptor FP (R3YFP). This elegant SRET approach has revealed the existence of distinct
higher-order GPCR oligomers in living cells, including the A2AR-D2R-CB1R complex and
the A2AR-D2R-mGlu5R oligomers mentioned previously [71,73].
Interestingly, two variations of the SRET approach, SRET1 and SRET2, have been
described. SRET1 involves catabolism of coelenterazine H by Rluc and the luciferase-
mediated emission (475 nm) provides energy for transfer to a nearby YFP (BRET1 process);
finally, YFP emission (527 nm) can result in a second energy transfer to DsRed. During
SRET2, the luciferase-mediated emission after Rluc catabolism of DeepBlueC (395 nm) is
able to excite GFP2 (BRET2 process) and the resulting FP emission (510 nm) can engage in
a second energy transfer to YFP (Figure 3a) [73]. Overall, the SRET method represents a
valuable technique for the study of trimeric PPIs and can further our understanding of how
proteins assemble and how these assemblies are governed by specific allosteric modulators
acting on their interfaces.
Integrating PCA assays and RET techniques
Recently, a new set of techniques combining PCA and RET assays has been developed for
the detection of trimeric and quaternary protein complexes. These approaches are based on
the use of a reconstituted YFP (BiFC) as an acceptor FP in a RET process. Thus, BiFC-
BRET and BiFC-FRET assays have been developed to demonstrate the existence of trimeric
GPCR complexes with spatial (BiFC-FRET) and temporal (BiFC-BRET and BiFC-FRET)
resolution [71,74–76]. The existence of higher-order oligomers is not restricted to GPCRs,
and these techniques can be used to investigate heterotrimeric G proteins or other trimeric
complexes comprising downstream effectors [52,77,78].
To demonstrate the existence of quaternary structures, it is possible to combine
bioluminescence or fluorescence complementation (BiLC or BiFC) and energy transfer
(RET). Receptors genetically fused to N- or C-terminal fragments of an LP or FP are
coexpressed in the same cell and if these form a tetravalent protein complex they can engage
in a RET process (Figure 3b). This approach led to detection of β2 adrenoceptor tetramers
[79]. It was also demonstrated that at least four D2Rs are located in close molecular
proximity when expressed in living cells, a phenomenon that is consistent with the notion
that they might be organized as higher-order oligomers or RMs at the plasma membrane
[80]. Identification of ternary and quaternary protein complexes has been possible by
combining PCA and RET approaches, catalyzed, in part, by research into GPCR
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oligomerization. Thus, the combination of these techniques will undoubtedly evolve as
widely used biotechnological tools for the identification and monitoring of PPIs not only at
the surface of living cells, but also at intracellular locations.
Concluding remarks
Fluorescence- and luminescence-based assays are useful tools for the visualization and
characterization of noncovalent PPIs in many cell types and organisms. In recent years, new
optical techniques based on RET and protein-fragment complementation have enabled
researchers to detect specific PPIs in diverse biological fields. Thus, as the use of these
approaches increases dramatically, it is timely to revise their significant strengths and
weaknesses to encourage reliable biotechnological exploitation of their present capabilities
and future potential. Fluorescence- and luminescence-based methods have been successfully
applied to the discovery of multimeric GPCR complexes in living cells; indeed, some of
these technical approaches are already patented because it is predicted that they will evolve
into powerful biotechnological tools in several research areas, such as drug discovery.
Despite their initial promise, it is becoming evident that these approaches need to pass some
technological barriers before they are fully incorporated into the biotechnological toolbox
as, for example, non-invasive techniques for discovering native PPIs in vivo. One obvious
drawback to these fluorescence- and luminescence-based methods is the ectopic expression
and/or overexpression of fusion proteins often required, which can lead to artefacts (e.g.
promotion or inhibition of PPIs). Consequently, when applied to the study of physiologically
relevant PPIs, physiological expression levels of the proteins under study should be
considered. The use of fluorescence- and luminescence-based approaches for PPI detection
in native tissue is still scarce and restricted to certain methods, namely the RET-based
techniques using antibodies against native proteins (i.e. TR-FRET), thus relying in the
specificity of the antibodies to success (Table 1). In conclusion, the discovery of GPCR
oligomerization exemplifies the power of the fluorescence/luminescence methods, and our
progressive understanding of these techniques will ensure further incorporation into the
‘everyday’ biotechnological toolbox.
Acknowledgments
This work was supported by grants SAF2008-01462 and Consolider-Ingenio CSD2008-00005 from Ministerio de
Ciencia e Innovación (to F.C.) and a start-up package from the Department of Pharmacology and Chemical
Biology, University of Pittsburgh and by the National Institutes of Health grants DK087688 (J.-P.V.). F.C. and
V.F.D. belong to the Neuropharmacology and Pain accredited research group (Generalitat de Catalunya, 2009 SGR
232). We thank Benjamín Torrejón and Esther Castaño from the Scientific and Technical Services (SCT)-Bellvitge
Campus of the University of Barcelona for technical assistance.
References
1. Miller J, Stagljar I. Using the yeast two-hybrid system to identify interacting proteins. Methods Mol
Biol. 2004; 261:247–262. [PubMed: 15064463]
2. Suter B, et al. Two-hybrid technologies in proteomics research. Curr Opin Biotechnol. 2008;
19:316–323. [PubMed: 18619540]
3. Selbach M, Mann M. Protein interaction screening by quantitative immunoprecipitation combined
with knockdown (QUICK). Nat Methods. 2006; 3:981–983. [PubMed: 17072306]
4. Ciruela F. Fluorescence-based methods in the study of protein–protein interactions in living cells.
Curr Opin Biotechnol. 2008; 19:338–343. [PubMed: 18602005]
5. Gandia J, et al. Light resonance energy transfer-based methods in the study of G protein-coupled
receptor oligomerization. Bioessays. 2008; 30:82–89. [PubMed: 18081019]
6. Wu P, Brand L. N-Terminal modification of proteins for fluorescence measurements. Methods
Enzymol. 1997; 278:321–330. [PubMed: 9170320]
Ciruela et al. Page 9













7. Becker CF, et al. C-Terminal fluorescence labeling of proteins for interaction studies on the single-
molecule level. ChemBiochem. 2006; 7:891–895. [PubMed: 16607669]
8. Palczewski K. G protein-coupled receptor rhodopsin. Annu Rev Biochem. 2006; 75:743–767.
[PubMed: 16756510]
9. Jaakola VP, et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to
an antagonist. Science. 2008; 322:1211–1217. [PubMed: 18832607]
10. Vilardaga JP, et al. Measurement of the millisecond activation switch of G protein-coupled
receptors in living cells. Nat Biotechnol. 2003; 21:807–812. [PubMed: 12808462]
11. Lohse MJ, et al. Monitoring receptor signaling by intramolecular FRET. Curr Opin Pharmacol.
2007; 7:547–553. [PubMed: 17919975]
12. Kristiansen K. Molecular mechanisms of ligand binding, signaling, and regulation within the
superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to
receptor structure and function. Pharmacol Ther. 2004; 103:21–80. [PubMed: 15251227]
13. Park PS, et al. Oligomerization of G protein-coupled receptors: past, present, and future.
Biochemistry. 2004; 43:15643–15656. [PubMed: 15595821]
14. Maggio R, et al. G protein-coupled receptor oligomerization provides the framework for signal
discrimination. J Neurochem. 2007; 103:1741–1752. [PubMed: 17868304]
15. Milligan G. G protein-coupled receptor hetero-dimerization: contribution to pharmacology and
function. Br J Pharmacol. 2009; 158:5–14. [PubMed: 19309353]
16. Canals M, et al. Adenosine A2A–dopamine D2 receptor–receptor heteromerization: qualitative and
quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem. 2003;
278:46741–46749. [PubMed: 12933819]
17. Pin JP, et al. International Union of Basic and Clinical Pharmacology. LXVII. Recommendations
for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol
Rev. 2007; 59:5–13. [PubMed: 17329545]
18. Vilardaga JP, et al. Conformational cross-talk between alpha2A-adrenergic and mu-opioid
receptors controls cell signaling. Nat Chem Biol. 2008; 4:126–131. [PubMed: 18193048]
19. Piston DW, Kremers GJ. Fluorescent protein FRET: the good, the bad and the ugly. Trends
Biochem Sci. 2007; 32:407–414. [PubMed: 17764955]
20. Wallrabe H, Periasamy A. Imaging protein molecules using FRET and FLIM microscopy. Curr
Opin Biotechnol. 2005; 16:19–27. [PubMed: 15722011]
21. Levitt JA, et al. Fluorescence lifetime and polarization-resolved imaging in cell biology. Curr Opin
Biotechnol. 2009; 20:28–36. [PubMed: 19268568]
22. Valentin G, et al. Photoconversion of YFP into a CFP-like species during acceptor photobleaching
FRET experiments. Nat Methods. 2005; 2:801. [PubMed: 16278647]
23. Mathis G. Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin
Chem. 1993; 39:1953–1959. [PubMed: 8375081]
24. Mathis G. Probing molecular interactions with homogeneous techniques based on rare earth
cryptates and fluorescence energy transfer. Clin Chem. 1995; 41:1391–1397. [PubMed: 7656455]
25. McVey M, et al. Monitoring receptor oligomerization using time-resolved fluorescence resonance
energy transfer and bioluminescence resonance energy transfer. The human delta-opioid receptor
displays constitutive oligomerization at the cell surface, which is not regulated by receptor
occupancy. J Biol Chem. 2001; 276:14092–14099. [PubMed: 11278447]
26. Milligan G, Bouvier M. Methods to monitor the quaternary structure of G protein-coupled
receptors. FEBS J. 2005; 272:2914–2925. [PubMed: 15955052]
27. Pfleger KD, Eidne KA. Illuminating insights into protein–protein interactions using
bioluminescence resonance energy transfer (BRET). Nat Methods. 2006; 3:165–174. [PubMed:
16489332]
28. Xu X, et al. Imaging protein interactions with bioluminescence resonance energy transfer (BRET)
in plant and mammalian cells and tissues. Proc Natl Acad Sci U S A. 2007; 104:10264–10269.
[PubMed: 17551013]
29. Hoshino H, et al. Luciferase–YFP fusion tag with enhanced emission for single-cell luminescence
imaging. Nat Methods. 2007; 4:637–639. [PubMed: 17618293]
Ciruela et al. Page 10













30. Mercier JF, et al. Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and
heterodimerization by bioluminescence resonance energy transfer. J Biol Chem. 2002; 277:44925–
44931. [PubMed: 12244098]
31. James JR, et al. A rigorous experimental framework for detecting protein oligomerization using
bioluminescence resonance energy transfer. Nat Methods. 2006; 3:1001–1006. [PubMed:
17086179]
32. Bouvier M, et al. BRET analysis of GPCR oligomerization: newer does not mean better. Nat
Methods. 2007; 4:3–4. [PubMed: 17195017]
33. Keppler A, et al. A general method for the covalent labeling of fusion proteins with small
molecules in vivo. Nat Biotechnol. 2003; 21:86–89. [PubMed: 12469133]
34. Keppler A, et al. Labeling of fusion proteins with synthetic fluorophores in live cells. Proc Natl
Acad Sci U S A. 2004; 101:9955–9959. [PubMed: 15226507]
35. Keppler A, et al. Labeling of fusion proteins of O6-alkylguanine-DNA alkyltransferase with small
molecules in vivo and in vitro. Methods. 2004; 32:437–444. [PubMed: 15003606]
36. Maurel D, et al. Cell-surface protein–protein interaction analysis with time-resolved FRET and
snap-tag technologies: application to GPCR oligomerization. Nat Methods. 2008; 5:561–567.
[PubMed: 18488035]
37. Gautier A, et al. An engineered protein tag for multiprotein labeling in living cells. Chem Biol.
2008; 15:128–136. [PubMed: 18291317]
38. Dorsch S, et al. Analysis of receptor oligomerization by FRAP microscopy. Nat Methods. 2009;
6:225–230. [PubMed: 19234451]
39. Michnick SW, et al. Universal strategies in research and drug discovery based on protein-fragment
complementation assays. Nat Rev Drug Discov. 2007; 6:569–582. [PubMed: 17599086]
40. Ghosh I, et al. Antiparallel leucine zipper-directed protein reassembly: application to the green
fluorescent protein. J Am Chem Soc. 2000; 122:5658–5659.
41. Remy I, Michnick SW. A highly sensitive protein–protein interaction assay based on Gaussia
luciferase. Nat Methods. 2006; 3:977–979. [PubMed: 17099704]
42. Stefan E, et al. Quantification of dynamic protein complexes using Renilla luciferase fragment
complementation applied to protein kinase A activities in vivo. Proc Natl Acad Sci U S A. 2007;
104:16916–16921. [PubMed: 17942691]
43. Nagai T, et al. Circularly permuted green fluorescent proteins engineered to sense Ca2+ Proc Natl
Acad Sci U S A. 2001; 98:3197–3202. [PubMed: 11248055]
44. Hu CD, et al. Visualization of interactions among bZIP and Rel family proteins in living cells
using bimolecular fluorescence complementation. Mol Cell. 2002; 9:789–798. [PubMed:
11983170]
45. Zhang S, et al. Combinatorial marking of cells and organelles with reconstituted fluorescent
proteins. Cell. 2004; 119:137–144. [PubMed: 15454087]
46. Massoud TF, et al. Reporter gene imaging of protein–protein interactions in living subjects. Curr
Opin Biotechnol. 2007; 18:31–37. [PubMed: 17254764]
47. Paulmurugan R, Gambhir SS. Combinatorial library screening for developing an improved split-
firefly luciferase fragment-assisted complementation system for studying protein–protein
interactions. Anal Chem. 2007; 79:2346–2353. [PubMed: 17295448]
48. Sadana R, et al. N terminus of type 5 adenylyl cyclase scaffolds Gs heterotrimer. Mol Pharmacol.
2009; 76:1256–1264. [PubMed: 19783621]
49. Dupre DJ, et al. The role of Gβγ subunits in the organization, assembly, and function of GPCR
signaling complexes. Annu Rev Pharmacol Toxicol. 2009; 49:31–56. [PubMed: 18834311]
50. Hynes TR, et al. Visualization of G protein βγ dimers using bimolecular fluorescence
complementation demonstrates roles for both β and γ in subcellular targeting. J Biol Chem. 2004;
279:30279–30286. [PubMed: 15136579]
51. Cabantous S, et al. Protein tagging and detection with engineered self-assembling fragments of
green fluorescent protein. Nat Biotechnol. 2005; 23:102–107. [PubMed: 15580262]
52. Heroux M, et al. Functional calcitonin gene-related peptide receptors are formed by the
asymmetric assembly of a calcitonin receptor-like receptor homo-oligomer and a monomer of
Ciruela et al. Page 11













receptor activity-modifying protein-1. J Biol Chem. 2007; 282:31610–31620. [PubMed:
17785463]
53. Hu CD, Kerppola TK. Simultaneous visualization of multiple protein interactions in living cells
using multicolor fluorescence complementation analysis. Nat Biotechnol. 2003; 21:539–545.
[PubMed: 12692560]
54. Shyu YJ, et al. Identification of new fluorescent protein fragments for bimolecular fluorescence
complementation analysis under physiological conditions. BioTechniques. 2006; 40:61–66.
[PubMed: 16454041]
55. Przybyla JA, Watts VJ. Ligand-induced regulation and localization of cannabinoid CB1 and
dopamine D2L receptor heterodimers. J Pharmacol Exp Ther. 2010; 332:710–719. [PubMed:
20016021]
56. Vidi PA, et al. Ligand-dependent oligomerization of dopamine D2 and adenosine A2A receptors in
living neuronal cells. Mol Pharmacol. 2008; 74:544–551. [PubMed: 18524886]
57. Fuxe K, et al. Intramembrane receptor-receptor interactions: a novel principle in molecular
medicine. J Neural Transm. 2007; 114:49–75. [PubMed: 17066251]
58. Fuxe K, et al. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal
function and Parkinson’s disease. Neurology. 2003; 61:S19–23. [PubMed: 14663004]
59. Fuxe K, et al. Adenosine–dopamine interactions in the pathophysiology and treatment of CNS
disorders. CNS Neurosci Ther. 2010; 16:e18–42. [PubMed: 20345970]
60. Park PS, Wells JW. Oligomeric potential of the M2 muscarinic cholinergic receptor. J Neurochem.
2004; 90:537–548. [PubMed: 15255931]
61. Lopez-Gimenez JF, et al. Theα1b-adrenoceptorexistsasa higher-order oligomer: effective
oligomerization is required for receptor maturation, surface delivery, and function. Mol
Pharmacol. 2007; 71:1015–1029. [PubMed: 17220353]
62. Philip F, et al. Signaling through a G protein-coupled receptor and its corresponding G protein
follows a stoichiometrically limited model. J Biol Chem. 2007; 282:19203–19216. [PubMed:
17420253]
63. Liang Y, et al. Organization of the G protein-coupled receptors rhodopsin and opsin in native
membranes. J Biol Chem. 2003; 278:21655–21662. [PubMed: 12663652]
64. Fotiadis D, et al. Structure of the rhodopsin dimer: a working model for G-protein-coupled
receptors. Curr Opin Struct Biol. 2006; 16:252–259. [PubMed: 16567090]
65. Jastrzebska B, et al. Functional and structural characterization of rhodopsin oligomers. J Biol
Chem. 2006; 281:11917–11922. [PubMed: 16495215]
66. Chabre M, et al. Biophysics: is rhodopsin dimeric in native retinal rods? Nature. 2003; 426:30–31.
[PubMed: 14603306]
67. Brock C, et al. Activation of a dimeric metabotropic glutamate receptor by intersubunit
rearrangement. J Biol Chem. 2007; 282:33000–33008. [PubMed: 17855348]
68. Fuxe K, et al. Heterodimers and receptor mosaics of different types of G-protein-coupled receptors.
Physiology (Bethesda). 2008; 23:322–332. [PubMed: 19074740]
69. Agnati LF, et al. Receptor–receptor interactions: a novel concept in brain integration. Prog
Neurobiol. 2010; 90:157–175. [PubMed: 19850102]
70. Ferre S, et al. Functional relevance of neurotransmitter receptor heteromers in the central nervous
system. Trends Neurosci. 2007; 30:440–446. [PubMed: 17692396]
71. Cabello N, et al. Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form
higher-order oligomers in living cells. J Neurochem. 2009; 109:1497–1507. [PubMed: 19344374]
72. Galperin E, et al. Three-chromophore FRET microscopy to analyze multiprotein interactions in
living cells. Nat Methods. 2004; 1:209–217. [PubMed: 15782196]
73. Carriba P, et al. Detection of heteromerization of more than two proteins by sequential BRET-
FRET. Nat Methods. 2008; 5:727–733. [PubMed: 18587404]
74. Gandia J, et al. Detection of higher-order G protein-coupled receptor oligomers by a combined
BRET-BiFC technique. FEBS Lett. 2008; 582:2979–2984. [PubMed: 18675812]
75. Navarro G, et al. Detection of heteromers formed by cannabinoid CB1, dopamine D2, and
adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence
Ciruela et al. Page 12













complementation and bioluminescence energy transfer. ScientificWorldJournal. 2008; 8:1088–
1097. [PubMed: 18956124]
76. Vidi PA, et al. Adenosine A2A receptors assemble into higher-order oligomers at the plasma
membrane. FEBS Lett. 2008; 582:3985–3990. [PubMed: 19013155]
77. Rebois RV, et al. Heterotrimeric G proteins form stable complexes with adenylyl cyclase and
Kir3.1 channels in living cells. J Cell Sci. 2006; 119:2807–2818. [PubMed: 16787947]
78. Shyu YJ, et al. Visualization of AP-1 NF-κB ternary complexes in living cells by using a BiFC-
based FRET. Proc Natl Acad Sci U S A. 2008; 105:151–156. [PubMed: 18172215]
79. Rebois RV, et al. Combining protein complementation assays with resonance energy transfer to
detect multipartner protein complexes in living cells. Methods. 2008; 45:214–218. [PubMed:
18586102]
80. Guo W, et al. Dopamine D2 receptors form higher order oligomers at physiological expression
levels. EMBO J. 2008; 27:2293–2304. [PubMed: 18668123]
81. Förster T. Zwischenmolekulare Energiewanderung und Fluoreszenz. Ann Phys. 1948; 2:55–75.
82. Cardullo RA. Theoretical principles and practical considerations for fluorescence resonance energy
transfer microscopy. Methods Cell Biol. 2007; 81:479–494. [PubMed: 17519181]
83. Stryer L, Haugland RP. Energy transfer: a spectroscopic ruler. Proc Natl Acad Sci U S A. 1967;
58:719–726. [PubMed: 5233469]
84. Stryer L. Fluorescence energy transfer as a spectroscopic ruler. Annu Rev Biochem. 1978; 47:819–
846. [PubMed: 354506]
85. Sheng M, Hoogenraad CC. The postsynaptic architecture of excitatory synapses: a more
quantitative view. Annu Rev Biochem. 2007; 76:823–847. [PubMed: 17243894]
86. Ferrandon S, et al. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis.
Nat Chem Biol. 2009; 5:734–742. [PubMed: 19701185]
87. Briddon SJ, et al. Plasma membrane diffusion of G protein-coupled receptor oligomers. Biochim
Biophys Acta. 2008; 1783:2262–2268. [PubMed: 18691614]
Ciruela et al. Page 13














Fluorescence-based methods used in the study of protein–protein interactions. (a) Schematic
representation of the basic FRET principle applied to the study of GPCR oligomerization.
Two putative receptors, R1 and R2, bear a donor CFP (R1CFP) and an acceptor YFP
fluorophore (R2YFP). If R1 and R2 interact, then the donor and acceptor fluorophores might
be in close proximity (≤10 nm) and energy transfer between the two fluorophores can occur
after donor excitation at 433 nm and emission at 475 nm and acceptor emission at 527 nm.
The schematic GPCR and FP diagrams were prepared using the PyMOL molecular graphics
system (DeLano Scientific), with the crystal structure of the sensory rhodopsin II and GFP
from Aequorea victoria (PDB 1JGJ and 1EMA, respectively) as models. (b) Example of the
DFRAP effect. Emission intensities of YFP (527 nm, yellow line) and CFP (480 nm, cyan
line) recorded from cells coexpressing the μ-opioid and α2A adrenergic receptors tagged at
the C-terminus with YFP and CFP, respectively. Emission intensities were recorded before
and after YFP (the acceptor fluorophore) was photobleached via 5-min exposure to light at
500 nm. Adapted with permission from [18]. (c) Schematic representations of various
technologies applied to the study of GPCR oligomerization. Two putative GPCRs, (i)
bearing a Myc and a Flag epitope tag on their N-terminal domains or fused to (ii) O6-
alkylguanine-DNA alkyltransferase (AGT; SNAP tag) or (iii) mutant O6-alkylguanine-DNA
alkyltransferase (AGT*; CLIP tag), are labeled with specific antibodies against these tag
sequences (i.e. Myc or Flag) or with specific substrates for either AGT or AGT*. The
antibodies are conjugated to the acceptor (APC; or d2 molecule) and the donor (K, Eu3+-
cryptate) FRET-pair fluorophore molecules. The SNAP-tag substrate O6-benzylguanine
(BG) is conjugated to the donor (K or Cy3) and the CLIP-tag substrate O6-benzylcytosine
(BC) to the acceptor (Cy5). The schematic AGT diagram was prepared using PyMOL (PDB
1EH6).
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Schematic representation of the basic principle of BiFC and multicolor BiFC. (a) Two
putative receptors, R1 and R2, each carry one half of YFP: R1 carries an N-terminal YFP
(R1N-YFP); R2 carries a C-terminal YFP (R2C-YFP). The interaction of R1 and R2 generates
a fluorescent complex formed by the two halves of YFP (N and C) and YFP fluorescence
can therefore be directly visualized after excitation at 500 nm. Corresponding confocal
microscopy images of HEK cells expressing the respective receptor constructs are shown
below the schematic. Scale bar, 10 μm. Adapted with permission from [87]. GPCR and FP
diagrams were prepared as described for Figure 1. (b) Application of multicolor BiFC to the
simultaneous detection of receptor homodimers and heterodimers. Receptor R1 carries an N-
terminal fragment of the Venus FP (R1VN), and receptor R2 carries either the N-terminus of
the Cerulean FP (R2CN) or the C-terminus of the Cerulean FP (R3CC). The relative amount
of heterodimer (R1/R2) versus homodimer (R2-R2) can be simultaneously visualized after
excitation at 500 nm (Venus) or 433 nm (Cerulean). (c) Receptor oligomerization in
response to drugs can be monitored using the approach in (b). For example, prolonged
treatment with a receptor agonist resulted in a decrease in Venus fluorescence at 527 nm as
measured against Cerulean fluorescence at 475 nm, thus indicating an agonist-induced
change in the GPCR homo-/heterodimer ratio (R2/R2 vs R1/R2). Adapted with permission
from [56], copyright © 2008 American Society of Pharmacology and Experimental
Therapeutics.
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Fluorescence-based methods used in the study of higher-order protein complexes. (a)
Schematic representation of the basic SRET principle applied to the study of GPCR
oligomerization. Three putative receptors, R1, R2 and R3 bearing a donor (Rluc), an
acceptor and donor (GFP2) and acceptor (YFP) chromophores, are depicted as R1Rluc,
R2GFP2 and R3YFP, respectively. When the three receptors are in close proximity, a
sequential double energy transfer (BRET-FRET) might occur: Rluc emission at 395 nm
excites GFP2; GFP2 emits at 510 nm, in turn exciting YFP, which then emits at 527 nm. The
schematic GPCR diagrams were prepared as described in Figure 1. The crystal structure of
luciferase from Renilla reniformis (PDB 2PSD) is shown. (b) The combination of PCA and
RET techniques allows for the detection of tetrameric receptor complexes (R1-R2-R3-R4).
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BiLC generates a complementary luminescent protein (Rluc) that acts as a donor in a BRET
process, with a complementary fluorescent acceptor protein (YFP) generated by BiFC. If
these receptors are in close proximity, then donor–acceptor energy transfer can occur after
Rluc substrate (coelenterazine H) oxidation. Excitation (475 nm) and emission (527 nm)
wavelengths are indicated.
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